65696 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 

20852, (240) 747–7530, mairi.noverr@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 19, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20656 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Population Assessment of Tobacco and 

Health (PATH) Study. 

Date: October 31, 2023. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Shareen Iqbal, Ph.D., 

M.P.H., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Research, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 443–4577, 

shareen.iqbal@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA– 

K Alternate SEP. 

Date: November 3, 2023. 

Time: 12:00 p.m. to 1:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Marisa Srivareerat, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 435–1258, 

marisa.srivareerat@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Animal Genomics and Functional 

Validation/Characterization of Genes/ 

Variants in SUD. 

Date: November 27, 2023. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 827–4471, 

ramadanir@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: September 20, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20693 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Research and Development 

of Vaccines and Monoclonal Antibodies for 

Pandemic Preparedness (ReVAMPP) Centers 

for Flaviviridae and Togaviridae (U19 

Clinical Trial Not Allowed). 

Date: October 24–25, 2023. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F30, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Scott Jakes, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3F30, Rockville, MD 

20852, (240) 669–5931, jakesse@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 20, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20695 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Request for Information on the DRAFT 

Scientific Integrity Policy of the 

National Institutes of Health 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Request for information. 

SUMMARY: The National Institutes of 

Health (NIH) is soliciting comments and 

suggestions from the public on the 

DRAFT ‘‘Scientific Integrity Policy of 

the National Institutes of Health’’ 

(DRAFT NIH Scientific Integrity Policy). 

The DRAFT NIH Scientific Integrity 

Policy codifies NIH’s long-standing 

expectations to preserve scientific 

integrity throughout all NIH activities, 

establishes key roles and 

responsibilities for those who will lead 

the agency’s scientific integrity program, 

and, as appropriate, establishes relevant 

reporting and evaluation mechanisms. 

DATES: The DRAFT ‘‘Scientific Integrity 

Policy of the National Institutes of 

Health’’ is open for public comment for 

a period of 45 days. To ensure 

consideration, comments must be 

submitted in writing by November 9, 

2023. 

ADDRESSES: Comments may be 

submitted electronically at https://

osp.od.nih.gov/comment-form-draftscientific-integrity-policy-for-thenational-institutes-of-health/. 


ddrumheller on DSK120RN23PROD with NOTICES1